The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Investigating the Neuroprotective Potential and Mechanism of Action of an Inhibitor of the Rho-associated Protein Kinase (ROCK)
Study Rationale: Altered signaling through the Rho-associated protein kinase (ROCK) pathway has been found to play a role in the cellular pathogenesis of Parkinson’s disease (PD). Previously, we...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Modulation of Glycine for the Treatment of Parkinson’s Disease
Study Rationale: Levodopa, currently the best treatment for the symptoms of Parkinson’s disease (PD), eventually leads to the development of uncontrollable involuntary movements, called dyskinesia. In...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Development of Small-molecule Inhibitors that Reduce the Aggregation of Tau for the Treatment of Parkinson’s Disease
Study Rationale: The aggregation of alpha-synuclein and tau converts these proteins from a biologically functional state into toxic, fibrous deposits in the brains of people with Parkinson’s disease...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Development of an Inhibitor of Tau Aggregation to Treat Parkinson’s Disease
Study Rationale: The formation of tau aggregates is caused by excessive modification and abnormal folding of the tau protein in the brain, which leads to cellular dysfunction and neurodegeneration...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Preclinical Development of Immune-inhibiting Small Molecules as Therapeutics for Parkinson’s Disease
Study Rationale: Brain inflammation plays an important role in the pathology of Parkinson’s disease (PD). One of the key proteins involved in this inflammatory process is STING (stimulator of...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Development of Novel Brain-penetrant Inflammasome Inhibitors as Potential Therapeutics for Parkinson’s Disease
Study Rationale: The immune system displays an aberrant pattern of activity in the central nervous system of people with Parkinson’s disease (PD); this pattern includes activation of a danger-sensing...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.